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Objectives
STAMPEDE is a multi-centre, randomised controlled
trial designed with novel multi-arm, multi-stage
(MAMS) methods. Here we: (1) describe the methodo-
logical and practical issues arising with the stopping of
recruitment to some trial arms following an intermedi-
ate analysis and (2) describe the issues surrounding the
addition of new research arms during the trial.
Methods
The trial recruits men with locally advanced or meta-
static prostate cancer starting standard long-term hor-
mone therapy. There are 5 research arms and 1 control
arm. The trial has a pilot stage assessing safety and fea-
sibility, 3 intermediate “activity” stages (I-III) where the
outcome measure is failure-free survival (FFS) and one
final “efficacy” stage (IV) with overall survival as primary
outcome measure. At the end of each stage, each
research arm is formally compared pairwise to the con-
trol arm. Accrual of further patients is discontinued
early for any research arm either not showing sufficient
evidence of activity or with adverse safety considera-
tions; accrual continues to arms showing activity with
acceptable safety. The stopping guideline compares the
treatment effect against a pre-defined cut-off value using
the hazard ratio when the hazards are proportional and
restricted-mean survival time otherwise. This interim
hurdle becomes increasingly stringent stage-by-stage.
The addition of new research arm(s) can be actively
considered when sufficiently interesting agents emerge.
New research arms are compared only to contempora-
neously-recruited control arm patients using the same
intermediate guidelines in a time-delayed manner. The
addition of new research arms is independent of any of
the original research arms stopping accrual early subject
to adequate recruitment to support the overall trial
aims.
Results
(1) After the second intermediate activity analysis
(March-2011), the IDMC recommended and the Trial
Steering Committee ratified discontinuation of recruit-
ment to two research arms for lack-of-sufficient activity.
Nearly 100 recruiting centres in UK and Switzerland
had to promptly implement the changes. Detailed
advanced preparation meant that activation was swift
and recruitment continued seamlessly into Activity
Stage III; MHRA and REC approval was not required
because this was already included in the trial design. (2)
An application to add a new research arm has been suc-
cessfully approved by the CRUK’s CTAAC funding com-
mittee and accepted by the relevant industry partner.
Details on the methodological and practical issues and
implementation of these changes will be presented.
Conclusions
The STAMPEDE experiences shows that recruitment to
MAMS trial is achievable and that mid-flow changes to
trial design are practicable with good planning.
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